Showing results (31-40 of 83) with videos related to

Sort By:
Pageof 9
World Journal of Clinical Cases|January 15, 2019
Risk factors for perforation during endoscopic retrograde cholangiopancreatography in post-reconstruction intestinal tractShinichi Takano, Mitsuharu Fukasawa, Hiroko Shindo, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|September 23, 2023
Significance of the autoantibody assay in predicting the development of immune-related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinomaHitomi Takada, Koji Yamashita, Leona Osawa, et al.
Oncology|September 29, 2025
Risk Factors for the Exacerbation of Esophageal Varices in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular CarcinomaHitomi Takada, Leona Osawa, Yasuyuki Komiyama, et al.
Cancer Science|December 28, 2021
Next-generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancerShinichi Takano, Mitsuharu Fukasawa, Hiroko Shindo, et al.
Biochemical and Biophysical Research Communications|May 7, 2008
T cell receptor-mediated signaling induces GRP78 expression in T cells: the implications in maintaining T cell viabilityShinichi Takano, Takashi Ando, Nobuhiko Hiramatsu, et al.
Cancer Medicine|January 17, 2021
Clinical significance of genetic alterations in endoscopically obtained pancreatic cancer specimensShinichi Takano, Mitsuharu Fukasawa, Hiroko Shindo, et al.
Cancer Science|August 8, 2009
DICKKOPF-4 and -2 genes are upregulated in human colorectal cancerAkira Matsui, Tatsuya Yamaguchi, Shinya Maekawa, et al.
Oncology|June 28, 2023
Relationship between Plasma IP-10/CXCL10 Levels and the Initial Therapeutic Response in Patients Treated with Atezolizumab plus Bevacizumab for Unresectable Hepatocellular CarcinomaHitomi Takada, Koji Yamashita, Leona Osawa, et al.
Oncology|December 14, 2022
Prediction of Therapeutic Response Using Contrast-Enhanced Ultrasound in Japanese Patients Treated with Atezolizumab and Bevacizumab for Unresectable Hepatocellular CarcinomaHitomi Takada, Koji Yamashita, Leona Osawa, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 29, 2024
Elevated nuclear expression of ZHX1 correlates with poor prognosis in hepatocellular carcinoma (HCC): Comparison of nuclear and cytoplasmic distribution of the ZHX family in HCC cellsYu-Hong Ma, Shinya Maekawa, Shinichi Takano, et al.
Pageof 9